-
Expression levels of genes implicated in the working mechanism of lenalidomide predict treatment response in lower risk myelodysplastic syndrome patients
HOVON89 study group, Mar 2025, In: Haematologica. 110, 3, p. 772-776 5 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Validation of the diagnostic potential of 17 immunophenotypic core markers defined by the ELN-iMDS-Flow Working Group in an independent cohort of patients with MDS
Veenstra, C. R., Alhan, C., Westers, T. M. & van de Loosdrecht, A. A., Mar 2025, In: HemaSphere. 9, 3, e70075.Research output: Contribution to journal › Article › Academic › peer-review
-
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
van de Loosdrecht, A. A., Cremers, E. M. P., Alhan, C., Duetz, C., in ’t Hout, F. E. M., Visser-Wisselaar, H. A., Chitu, D. A., Verbrugge, A., Cunha, S. M., Ossenkoppele, G. J., Janssen, J. J. W. M., Klein, S. K., Vellenga, E., Huls, G. A., Muus, P., Langemeijer, S. M. C., de Greef, G. E., te Boekhorst, P. A. W., Raaijmakers, M. H. G. & van Marwijk Kooy, M. & 20 others, , Apr 2024, In: Leukemia. 38, 4, p. 840-850 11 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
